Elanco Animal Health received a U.S. Food and Drug Administration Emergency Use Authorization for its Negasunt Powder and a U.S. Environmental Protection Agency Section 18 Emergency Exemption for Tanidil on April 27 2026. The authorizations allow veterinarians and livestock producers to use the products in cattle, swine, goats, sheep, horses, and donkeys in areas where the New World screwworm is detected or could enter the United States.
Negasunt Powder contains the insecticides coumaphos, propoxur, and sulfanilamide, while Tanidil contains coumaphos and propoxur. Both products carry a boxed warning for neurotoxicity, a 28‑day withdrawal period for food‑producing animals, and a prohibition on use in dairy cattle. The FDA and EPA approvals provide a rapid, science‑based response to the reemerging screwworm threat that was eradicated in the U.S. in 1966 but has been advancing northward since 2022.
The authorizations give Elanco a first‑mover advantage in a high‑risk disease that could threaten livestock production across the country. The company’s strategy of rapid product deployment and market protection is reinforced by these approvals, which enable Elanco to respond quickly to potential infestations and support producers in affected regions.
Elanco’s portfolio has delivered 4 % organic constant‑currency revenue growth, with accelerating performance in its Pet Health segment and consistently strong execution in Farm Animal. Management has emphasized the importance of these emergency authorizations as part of the company’s broader focus on protecting livestock producers and maintaining a robust pipeline of high‑impact products.
Distribution of Negasunt Powder and Tanidil will be coordinated through the U.S. Animal Plant Health and Inspection Service and its National Veterinary Stockpile, in partnership with state animal health officials and federally recognized tribal agencies. Initial access is limited to authorized government personnel, with the possibility of expanding to licensed veterinarians in infested zones if an incursion occurs.
Elanco’s spokesperson said the company is committed to working alongside state and federal regulatory authorities to provide support and scientific expertise. The company’s leadership has highlighted the rapid deployment of these products as a key element of its strategy to protect livestock producers and to strengthen its position in the Farm Animal market.
While no immediate market reaction data are available, the regulatory approvals open a new revenue stream for Elanco and strengthen its competitive position in the animal health industry. The authorizations also signal the company’s readiness to address emerging threats and reinforce its reputation as a proactive provider of animal health solutions.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.